We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLGL:NASDAQSol-Gel Technologies Ltd. Analysis

Data as of 2026-08-31 - not real-time

$69.85

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Sol-Gel Technologies Ltd. is bullish at $69.85, with short-term averages leading the long-term ones. It has lost 12.8% over the past 30 days. RSI sits at 38.8, which reads as approaching oversold, and MACD momentum is bearish. Price has been bracketed by support at $66.15 and resistance at $90.79.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 181.6% above today's level. Revenue is contracting at 96.6%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 86.3%, a beta of 0.94 and a maximum drawdown of 35.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top Market Events

Pivotal Phase 3 clinical trial of SGT-610 patidegib gel, 2% for Gorlin syndrome remains ongoing, with top-line results...donanimhaber.com3monSol-Gel Technologies SLGL Q4 2025 Earnings: Development-Stage Miss Deepens as Losses Widen; Stock...Detailed price information for Sol-Gel Technologies Ltd SLGL-Q from The Globe and Mail including charting and trades.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 68.68
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 68.68
  • Analyst targets imply +181.6% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +181.6% versus the current price
  • Negative return on equity of -40.9%
  • Revenue contracting at -96.6%

Key Metrics & Analysis

Financial Health

Revenue Growth-96.60%
P/E Ratio-9.1
ROE-40.85%
ROA-23.87%
Debt/Equity1.60
P/B Ratio4.8
Op. Cash Flow$-8542000
Free Cash Flow$-2120250
Industry P/E30.4

Technical Analysis

TrendBullish
RSI38.8
Support$66.15
Resistance$90.79
MA 20$79.86
MA 50$78.67
MA 200$68.68
MACDBearish
VolumeDecreasing
Fear & Greed Index94.43

Valuation

Target Price$196.67
Upside/Downside181.56%
GradeFair
TypeBlend

Risk Assessment

Beta0.94
Volatility86.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.